protein biomarker in patient's peripheral blood monocytes (PBMCs) that can be
used to predict the response to anti-TNF treatment.
Solved by the Technology:
with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) endure synovial
inflammation and joint destruction caused by excessively high levels of tumor
necrosis factor (TNF) in both the circulation and within the affected joints.
Anti-TNF therapy is commonly used to treat RA and PsA. However, only 50 - 60% of
patients respond to this therapy, and less than 25% achieve true remission with
protein marker will be the first predictor of patient response to anti-TNF
therapy. It can be further developed into a PBMC-based companion diagnostic test
for the anti-TNF regimen, either by flow cytometry or Western blotting using
PBMCs. Patients who are predicted to be unresponsive to anti-TNF therapy can
thus start alternative treatment right away to avoid unnecessary joint
inflammation and destruction while being spared the costs associated with the
initial anti-TNF treatments.
mouse studies have shown that this biomarker is up-regulated in response to
increased TNF levels in the blood. Extended human studies further revealed that
the protein levels in PBMCs were elevated in 50 - 60% of RA and PsA patients.
More importantly, normal protein levels were observed in >90% of patients who
responded positively to anti-TNF treatment. This discovery is currently being
verified in a larger patient population.